This meeting took place in 2016


Here are the related meetings in 2017:
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)


Organizer(s) Barbara Seliger, Jerome Galon and Francesco M. Marincola
January 24—28, 2016
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Discounted Abstract Deadline: Sep 29, 2015
Abstract Deadline: Oct 29, 2015
Scholarship Deadline: Sep 29, 2015
Discounted Registration Deadline: Nov 24, 2015

Sponsored by BioLegend, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Joint Meeting: Purinergic Signaling (J5)

Summary of Meeting:
This meeting focuses on immune escape mechanisms, immune tolerance, the role of immune effector and suppressor cells as well as the tumor microenvironment in this context, and the modulation of these different processes. In addition, the modes and efficacy of different cancer immunotherapeutic strategies and targeted therapies alone and in combination as well as their influence on the immune escape and immune suppressive activity will be an important topic. This meeting is expected to attract a broad range of scientists (e.g., biologists, biochemists, immunologists, cancer researchers) and clinicians (oncologists, pathologists, radiologists) and will bridge basic, translational and clinical research. The speakers invited represent basic researchers, clinicians and employees of the pharmaceutical industry. There will be a strong clinical focus to the program, in particular regarding different therapeutic strategies including cancer immunotherapy and targeted therapies, which have recently been successfully implemented for the therapy of many cancers including chronic myeloid leukemia, breast carcinoma, non-small lung carcinoma, colorectal cancer, kidney cancer and melanoma.

View Meeting Program

Scholarships/Awards

Keystone Symposia Future of Science Fund Scholarship Recipients

Anushka Dongre
Whitehead Institute for Biomedical Research, USA

Rachel Yamin
Hebrew University, Israel

The Elkes Foundation Scholarship Recipients

Nikhil S. Joshi
Yale University School of Medicine, USA